Telix在日本开始第3阶段试验,测试新的前列腺癌成像药物Illuccix。 Telix begins Phase 3 trial in Japan to test new prostate cancer imaging drug Illuccix.

在日本的前列腺癌成像中,Telix Pharmaceuticals 公司为第一个患者提供了TLX591- Px (Illuccix) 关键的第三期试验. Telix Pharmaceuticals has dosed the first patient in a pivotal Phase 3 trial of TLX591-Px (Illuccix) for prostate cancer imaging in Japan. 在日本Illuccix的研究中,有多达105名日本男子在外科手术后经常患前列腺癌,该研究将把68Ga-PSMA-11 PET/CT成像与常规CT和检测转移的骨癌扫描进行比较。 The Illuccix Japan study, enrolling up to 105 Japanese men with recurrent prostate cancer after surgery, will compare 68Ga-PSMA-11 PET/CT imaging to conventional CT and bone scans in detecting metastases. 审判旨在评估敏感性、诊断准确性、安全性以及对治疗决定的影响,支持今后在日本获得批准。 The trial aims to assess sensitivity, diagnostic accuracy, safety, and impact on treatment decisions, supporting future approval in Japan. 这与Telix自2024年以来的同情性使用供应相继, 并解决在一个每年新增104,000多例前列腺癌病例的国家有限获得PSMA-PET成像服务的问题。 This follows Telix’s compassionate use supply since 2024 and addresses limited access to PSMA-PET imaging in a country with over 104,000 new prostate cancer cases annually.